Seminar Title: Ewing sarcoma is an “enhancer disease”: from epigenetic heterogeneity to patient stratification and targeted therapies
Short Bio: Eleni M. Tomazou is a principal investigator at the Children‘s Cancer Research Institute (CCRI) in Vienna, Austria. She studies the role of epigenetics and enhancer reprogramming in pediatric sarcomas, with the goal to establish epigenome-based precision medicine approaches. Prior to joining CCRI, she did her PhD at the Wellcome Sanger Institute (Cambridge, UK) and postdoctoral training at the Broad Institute and the Harvard Department for Stem Cell and Regenerative Biology (Cambridge, USA). She is a 2016 recipient of the Elise Richter Fellowship, a prestigious career development grant for female scientists offered by the Austrian Science Foundation (FWF). She has recently received an ERC consolidator grant (SARCOMAkids project; ERC-COG 2022). With this project, her group aims to build developmentally programmed pediatric sarcomas in order to establish a versatile platform for drug discovery and molecular precision medicine for these hard to treat tumors.
Short Bio: Eleni M. Tomazou is a principal investigator at the Children‘s Cancer Research Institute (CCRI) in Vienna, Austria. She studies the role of epigenetics and enhancer reprogramming in pediatric sarcomas, with the goal to establish epigenome-based precision medicine approaches. Prior to joining CCRI, she did her PhD at the Wellcome Sanger Institute (Cambridge, UK) and postdoctoral training at the Broad Institute and the Harvard Department for Stem Cell and Regenerative Biology (Cambridge, USA). She is a 2016 recipient of the Elise Richter Fellowship, a prestigious career development grant for female scientists offered by the Austrian Science Foundation (FWF). She has recently received an ERC consolidator grant (SARCOMAkids project; ERC-COG 2022). With this project, her group aims to build developmentally programmed pediatric sarcomas in order to establish a versatile platform for drug discovery and molecular precision medicine for these hard to treat tumors.